Neoadjuvant Niraparib Shows Early Promise in BRCA-Mutated, HRD+ Ovarian Cancer

Article

Neoadjuvant niraparib induced strong results for patients with BRCA-mutant, homologous repair deficient–positive advanced resectable ovarian cancer.

ovarian cancer

Neoadjuvant niraparib (Zejula) induced strong results for patients with BRCA-mutant, homologous repair deficient (HRD)–positive advanced resectable ovarian cancer, in preliminary results from the phase 2 NANT trial (NCT04507841) presented at the 2022 SGO Annual Meeting on Women’s Cancer.1 

“Neoadjuvant niraparib monotherapy shows efficacy and tolerable toxicity in BRCA mutation, HRD-positive patients with advanced unresectable ovarian cancer,” said presenting author Qinglei Gao, MD, PhD, a professor with Tongji Medical College at Huazhong University of Science and Technology in Wuhan, China.

Among the 8 patients who have completed niraparib monotherapy, the objective response rate (ORR) was 75%. All responses were partial. “The maximum decline in target lesions was nearly 60%,” Gao added. “The R0 resection rate was 57.1% in 4 patients with BRCA mutation.”

Two patients (28.6%)—one with HRD-positive, BRCA wild-type tumors and 1 with BRCA mutation—had R1 resection and 1 patient (14.3%) with HRD-positive, BRCA wild-type tumors had R2 resection.

Patients aged 18-75 years with newly diagnosed HRD-positive, FIGO stage III-IV ovarian cancer were eligible for this multicenter, prospective, single-arm, open-label, study. Investigators determined HRD status by next-generation sequencing.2

Enrolled patients received niraparib at a daily dose of 200 mg or 300 mg for 2 four-week cycles. Following neoadjuvant niraparib treatment, patients exhibiting complete response, partial response, or stable disease will proceed to tumor reduction surgery and subsequent standard carboplatin/paclitaxel-based chemotherapy.

The primary end points include ORR and R0 resection rate. Secondary end points include rate of treatment interruption/termination, progression-free survival (PFS), overall survival, and disease control rate.

The study uses Simon’s optimal two-stage design, with 24 and 21 patients planned for the first and second stage, respectively. Five patients were necessary to determine preliminary ORR in stage 1 and 8 for stage 2. Gao presented results from stage 1 of the 2-stage trial. Investigators plan to present updated data after completion of stage 2.

The median age for these 8 patients was 51.5 years (range, 36-60), all of whom had high-grade serous carcinoma. Six (75%) patients had FIGO stage IIIC disease and 2 (25%) had stage IV. Five (62.5%) patients had an ECOG score of 1 and 3 (37.5%) had a store of 2. Similarly, 5 patients had BRCA mutations and 3 had BRCA wild type. All patients were positive for ascites.

Investigators measured CA125 levels every 2 weeks and observed a decline starting at day 14 after the first dose of niraparib. CA125 levels declined by a median of 57.6% following the first cycle of treatment and by a median of 88.5% following the second cycle.

Twenty patients were evaluable for treatment-emergent adverse events (TEAEs). Sixteen (80%) experienced any-grade TEAEs and 13 (65%) experienced grade 3 or higher TEAEs. The most common such events were hematological.

Anemia was the most common grade 3 or higher TEAE, followed by leukopenia and thrombocytopenia. Thrombocytopenia was most common following the first cycle of treatment, concurrent with the decline of CA125.

One (5%) patient required dose reduction. Twelve (60%) needed treatment interruption and 2 (10%) discontinued treatment. There were no treatment-related deaths.

In November 2021, Zai Lab Limited announced that topline data from the phase 3 PRIME trial (NCT03705156) First-line maintenance treatment with the PARP inhibitor niraparib (Zejula) yielded a clinically meaningful and statistically significant improvement in PFS compared with placebo in Chinese patients with platinum-responsive advanced ovarian cancer regardless of biomarker status.3

Results showed that the study met its primary end point of PFS and demonstrated a tolerable safety profile in those with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, following a response to platinum-based chemotherapy.

The PRIME study enrolled 384 patients with advanced ovarian cancer who achieved a complete response or partial response to first-line platinum-based chemotherapy. Patients were assigned niraparib or placebo until disease progression. The starting dose of niraparib was individualized at 200 mg except for in patients with a baseline body weight 77 kg or more and a platelet count of 150K/μL or more, in which case the starting dose increased to 300 mg.

Zai Lab plans to present the PRIME study data at a future medical conference.

References

  1. Yang Y, Zhang W, Liu R, et al. Effectiveness and safety of niraparib as neoadjuvant therapy in advanced ovarian cancer with homologous recombination deficiency: a prospective, multicenter, exploratory, phase 2 single-arm study (NANT). 2022 SGO Annual Meeting on Women’s Cancer. March 18-21, 2022. Phoenix, Arizona.
  2. Zhou D, Liu J, Liu R, et al. Effectiveness and safety of niraparib as neoadjuvant therapy in advanced with homologous recombination deficiency (NANT): study protocol for a prospective, multicenter, exploratory, phase 2, single-arm study. Front Oncol. Published online February 28, 2022. doi: 10.3389/fonc.2022.852772
  3. Zai Lab announces positive topline results from phase 3 PRIME study of Zejula® (niraparib) as first-line monotherapy maintenance treatment in Chinese women with platinum-responsive advanced ovarian cancer. Zai Lab. Published November 30, 2021. Accessed March 19, 2022. https://bit.ly/3I4Coof
Related Videos
Sumanta Kumar Pal, MD, FASCO,
Amin Nassar, MD
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Emil Lou, MD, PhD, FACP
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus
Hye Sook Chon, MD, gynecologic oncologist, Gynecologic Oncology Program, Moffitt Cancer Center
Amma Asare, MD, PhD